Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.890
-0.020 (-1.05%)
At close: Sep 18, 2026, 4:00 PM EDT
1.900
+0.010 (0.53%)
After-hours: Sep 18, 2026, 4:10 PM EDT

Innate Pharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
174173166233282400
Market Cap Growth
-11.35%4.71%-29.08%-17.19%-29.50%19.60%
Enterprise Value
184135107180196283
Last Close Price
1.911.751.842.803.734.56

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
15.4916.407.953.434.5814.24
PB Ratio
--6.8018.114.074.873.27
P/TBV Ratio
--18.114.105.025.56

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
16.4512.735.152.653.1910.07

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
-0.50-1.043.510.770.780.41
Net Debt / Equity Ratio
-0.230.54-5.63-1.01-1.09-0.70
Net Debt / EBITDA Ratio
-0.200.220.996.164.931.75
Net Debt / FCF Ratio
-0.220.226.831.603.011.27
Asset Turnover
0.150.100.140.330.250.09
Quick Ratio
0.601.142.503.513.211.67
Current Ratio
0.601.272.603.733.381.73
Return on Equity (ROE)
---162.91%-14.28%-71.75%-34.53%
Return on Assets (ROA)
-46.60%-38.85%-22.52%-4.23%-4.40%-10.40%
Return on Invested Capital (ROIC)
-2545.08%----122.70%-173.03%
Return on Capital Employed (ROCE)
-2545.10%-207.20%-66.10%-9.30%-10.40%-25.50%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-31.23%-33.30%-30.93%-3.58%-22.02%-15.02%
FCF Yield
-28.28%-35.82%-4.56%-15.58%-7.46%-16.89%
Buyback Yield / Dilution
-10.65%-10.54%-0.74%-1.02%-0.12%-0.77%
SEC Filings: 10-K · 10-Q